Megestrol acetate NCD oral suspension - Par Pharmaceutical

Drug Profile

Megestrol acetate NCD oral suspension - Par Pharmaceutical

Alternative Names: Megace ES oral suspension; Megestrol acetate NanoCrystal® Dispersion oral suspension; Megestrol Alkermes; PAR-100.2

Latest Information Update: 16 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Par Pharmaceutical
  • Class Antiandrogens; Antineoplastics; Pregnadienes; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anorexia; Cachexia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Nov 2015 Par Pharmaceutical Inc has been acquired by Endo International
  • 28 Jul 2015 First generic equivalent available in USA for Anorexia and Cachexia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top